New Research Links Serotonin Signaling to Mitral Valve Degeneration

Recent clinical research published in Science Translational Medicine indicates that serotonin signaling may play a significant role in the progression of degenerative mitral regurgitation (DMR). While serotonin is primarily recognized for its influence on mood, sleep, and digestion, evidence suggests that reduced activity of the serotonin transporter (SERT) can accelerate structural changes in mitral valve tissue. This discovery highlights a potential biological pathway that may influence how quickly heart valves deteriorate in patients with existing valve disease.

The Role of Serotonin and Transporter Activity in Heart Valves

Serotonin acts as a chemical messenger throughout the human body, attaching to cell surface receptors to trigger specific responses. A protein called the serotonin transporter (SERT or 5-HTT) is responsible for reabsorbing serotonin into cells, effectively ending the signal. Selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine (Prozac) and sertraline (Zoloft), function by reducing SERT activity, which increases the availability of serotonin.

Researchers led by Giovanni Ferrari, PhD, of Columbia University and Robert J. Levy, MD, of the Children’s Hospital of Philadelphia investigated whether this mechanism could unintentionally affect heart valve tissue. Their findings, supported by the National Heart, Lung, and Blood Institute, suggest that in valves already weakened by degeneration, reduced SERT activity may contribute to the buildup of excess collagen. This process can cause the valve to become thicker and stiffer, impairing its ability to seal correctly during the heart’s contraction cycle.

Clinical Observations and Genetic Susceptibility

The research team analyzed clinical data from more than 9,000 patients who underwent mitral valve repair or replacement. The study found an association between SSRI use and the need for surgical intervention at a younger age in patients with DMR. However, as an observational study, these findings do not establish a direct cause-and-effect relationship between antidepressant use and valve disease progression.

To further understand the biological mechanism, researchers examined the 5-HTTLPR region of the SERT gene. They identified a “long” genetic variant associated with lower SERT activity. Patients with DMR who carried two copies of this variant (the “long-long” genotype) required mitral valve surgery more frequently than those with other genetic profiles. Laboratory experiments confirmed that mitral valve cells from these individuals were more sensitive to serotonin and produced higher levels of collagen when exposed to it.

What This Means for Patients and Clinical Care

It is important to note that these findings do not suggest that SSRIs cause damage to healthy heart valves. Giovanni Ferrari noted that healthy mitral valves can likely withstand fluctuations in SERT activity without deforming. Furthermore, experts emphasize that patients should not discontinue or alter their antidepressant medications without direct guidance from their prescribing clinician.

While the researchers proposed that genetic testing for the 5-HTTLPR variant could potentially help identify patients who require closer monitoring or earlier surgical intervention, such testing is not currently a standard component of clinical heart valve care. Major medical guidelines continue to prioritize established metrics, including:

• Symptom assessment
• Valve anatomy and structural imaging
• Severity of the mitral leak (regurgitation)
• Cardiac and pulmonary function testing

Future Directions in Heart Valve Research

The connection between serotonin and valve remodeling remains an active area of investigation. Subsequent studies have explored whether other receptors, such as HTR2B, could serve as targets for future therapies to prevent fibrotic changes in heart valves. While experimental compounds blocking HTR2B have shown promise in preclinical models, these treatments are not currently approved for clinical use. Additional longitudinal human trials are necessary to determine if targeting the serotonin pathway can safely improve outcomes for patients with degenerative heart valve disease.